HEP DART 2019: Frontiers in Drug Development for Hepatology

摘要/项目摘要： Hep Dart：肝病药物开发的前沿是一个独立的两年一次的会议 在过去的24年里，吸引了至少250人参加。Hep Dart向任何有兴趣的人开放 病毒性肝炎和慢性肝病的治疗。这次会议的内容发展到 兴趣主要是科学家和临床研究人员，重点是药物开发和 疫苗学。HEP DART 2019的目标是召集临床医生、研究人员、基础科学家、护士 和医生助理一起促进我们对正在进行的药物开发的了解 非酒精性病毒性肝炎(乙肝、丙型肝炎、丁型肝炎、甲型肝炎和戊型肝炎)的治疗进展 脂肪性肝炎(NASH)和肝细胞癌(HCC)。Hep Dart将独一无二地混合 为生物、化学、药理学和临床研究领域提供科学界 随着对肝脏感染治疗方法当前和未来挑战的了解不断加深， 疾病和癌症。目的：(1)重点介绍抗病毒性肝炎药物的研究进展 如乙肝病毒、丙型肝炎病毒和HDV。(2)描述乙肝治疗策略的最新进展。(3) 重点介绍抗NASH、纤维化和肝细胞癌的药物开发进展。(4)描述小说 病毒性肝炎、肝病和治疗结果的生物标志物。(5)审查目前的治疗方法和 病毒性肝炎疫苗接种指南；描述改进治疗方案的进展。(6) 了解乙肝病毒感染和NASH在儿科和青少年人群中的后果。(7) 评估疫苗和治疗性疫苗在未来治疗病毒性肝炎、NASH和 共同-感染艾滋病毒。(8)了解HDV、HAV和HEV的流行病学和发病机制。 方法：HEP DART 2019包括为期四天的科学报告，以口头和口头两种形式进行 和海报演示格式通过非-并发会话。埃默里大学办公室 继续医学教育将HEP DART指定为最多24个1类学分 美国医学会医师认可奖。Hep Dart提供了一个轻松和科学刺激的 为博士和医学博士提供相互联系和共同学习的氛围。请求支持以帮助支付 青年调查员、妇女、可见的少数群体和其他人的奖学金和旅费 代表人数不足。

Abstract/ Project summary: HEP DART: Frontiers in Drug Development for Hepatology is an independent biennial conference attracting at least 250 attendees for the past 24 years. HEP DART is open to anyone interested in therapies for viral hepatitis and chronic liver disease. The content of this conference was developed to interest primarily scientists and clinical researchers with a focus on drug development and vaccinology. The aim of HEP DART 2019 is to assemble clinicians, researchers, basic scientists, nurses and physician assistants together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non‐‐‐alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). HEP DART will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for liver infection, disease and cancer. OBJECTIVES: (1) Highlight advances in drug development against viral hepatitis such as HBV, HCV, and HDV. (2) Describe the latest developments in HBV curative strategies. (3) Highlight advances in drug development against NASH, fibrosis and HCC. (4) Describe novel biomarkers for viral hepatitis, liver disease, and treatment outcomes. (5) Review current treatment and vaccination guidelines for viral hepatitis; describe advancements in improved treatment regimens. (6) Understand the consequences of HBV infection and NASH in pediatrics and adolescent populations. (7) Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis, NASH, and co‐‐‐infections with HIV. (8) Understand the epidemiology and pathogenesis of HDV, HAV and HEV. METHODS: HEP DART 2019 comprises four days of scientific presentations, delivered in both oral and poster presentations formats via non‐‐‐concurrent sessions. Emory University, Office of Continuing Medical Education designates HEP DART for a maximum 24 category 1 credits toward the AMA Physician’s Recognition Award. HEP DART provides a relaxed and scientifically stimulating atmosphere for both PhDs and MDs to network and learn together. Support is requested to help defray costs of scholarships and travel grants for young investigators, women, visible minorities and other under‐‐‐represented delegates.